Avalo TherapeuticsAVTX
AVTX
About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Employees: 23
0
Funds holding %
of 7,299 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
18% more capital invested
Capital invested by funds: $56M [Q4 2024] → $66.1M (+$10.2M) [Q1 2025]
5.37% more ownership
Funds ownership: 71.99% [Q4 2024] → 77.37% (+5.37%) [Q1 2025]
3% more funds holding
Funds holding: 33 [Q4 2024] → 34 (+1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
225%
upside
Avg. target
$25
435%
upside
High target
$36
681%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor | 225%upside $15 | Buy Assumed | 2 Jun 2025 |
Jefferies Kambiz Yazdi | 399%upside $23 | Buy Initiated | 25 Mar 2025 |
Stifel Alex Thompson | 681%upside $36 | Buy Initiated | 25 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.
Neutral
GlobeNewsWire
1 month ago
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025.
Neutral
GlobeNewsWire
1 month ago
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET.
Neutral
GlobeNewsWire
2 months ago
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company.
Positive
Benzinga
2 months ago
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. AVTX. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb targeting inflammatory diseases.
Neutral
GlobeNewsWire
2 months ago
Avalo Reports 2024 Financial Results and Recent Business Updates
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md.
Neutral
GlobeNewsWire
3 months ago
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March.
Neutral
GlobeNewsWire
4 months ago
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET.
Neutral
GlobeNewsWire
5 months ago
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization.
Neutral
GlobeNewsWire
7 months ago
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement.
Charts implemented using Lightweight Charts™